NaPro receives paclitaxel administration patent

NaPro BioTherapeutics in Boulder, CO, has been granted a U.S. patent relating to a novel method of administering paclitaxel. This patented method involves administrating smaller, more frequent doses of the drug over a shorter infusion time compared with the administration schedule currently approved by the FDA for Bristol-Meyers Squibb's paclitaxel product.

However, the patent application was based on data derived from in vitro and animal stud-ies and treatment of cancer patients using the patented method, and no controlled clinical trials have been performed.